Jefferies & Co announced Kadmon Holdings (NYSE:KDMN), upping its target price to $12.00 today
- Updated: September 17, 2016
Yesterday Kadmon Holdings (NYSE:KDMN) traded 3.41% lower at $9.97. KDMN’s 50-day average is $9.71 and its two hundred day moving average is $9.71. The last stock close is up 24.12% relative to the 200-day moving average, compared with the S&P 500 which has fallen -0.01% over the same time. Volume of trade was was down over the average, with 43,003 shares of KDMN changing hands under the typical 103,248 shares..
In a report issued 8/22/2016 Jefferies & Co increased the target price of Kadmon Holdings (NYSE:KDMN) from $0 to $12 indicating a possible upsideof 0.20%.
With a total market value of $0.0, Kadmon Holdings has a P/E of 0 with a 52 week low of $7.29 and a 52 week high of $10.48.
About Kadmon Holdings (NYSE:KDMN)
Kadmon Holdings, Inc., formerly Kadmon Holdings, LLC, is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of small molecules and biologics. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. The Company offers KD025, Tesevatinib in Oncology, Tesevatinib in polycystic kidney disease (PKD) and KD034. It offers tablets and capsules, such as Ribasphere RibaPak, Ribasphere tablets, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is its candidate in its rho-associated coiled-coil kinase 2 (ROCK2) platform, which is an oral, selective ROCK2 inhibitor. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block molecular drivers of tumor growth, metastases and drug resistance. KD034 is its portfolio of formulations of trientine hydrochloride, a chelating compound for the removal of excess copper from the body, and for the treatment of Wilson’s disease.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.